Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib maintenance in high-risk pediatric solid tumors
NCT05135975Phase 2Recruiting
- Sponsor
- Nationwide Children's Hospital
- Start
- Jul 2022
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in neuroblastoma, Ewing sarcoma, osteosarcoma (OS) and 4 more, sponsored by Nationwide Children's Hospital. Primary endpoint: 1-Year Progression-Free Survival. Started Jul 2022; status: recruiting.
02
Drugs
cabozantinib
03
Conditions
neuroblastomaEwing sarcomaosteosarcoma (OS)rhabdomyosarcoma (RMS)Wilms' tumor
Beyond the preview
Go deeper on NCT05135975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05135975.